Browse Categories

Publications by authors named "Pablo E Puente"

  • Page 1 of 1
Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis.
Matthew D Gregory Kweku Ofosu-Asante Jassy Mary S Lazarte Pablo E Puente Nada Tawfeeq

PLoS One

October 2024

Article Synopsis
  • - KRAS mutations are prevalent in lung adenocarcinoma among Black Americans, leading to the exploration of Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) as potential therapies to disrupt hyperactive G-protein signaling caused by mutated RAS proteins.
  • - Among 17 PCAIs tested, NSL-YHJ-2-27 and NSL-YHJ-2-46 demonstrated significant potency in affecting KRAS-mutated lung cancer cells, with EC50 values of 2.7 μM and 3.3 μM, and notable changes in MAPK pathway enzyme phosphorylation.
  • - Treatment with these PCAIs led to decreased levels of key G-proteins linked to cell migration
View Article and Find Full Text PDF
Lack of racial and ethnic diversity in lung cancer cell lines contributes to lung cancer health disparities.
Christopher Leon Eugene Manley Aaron M Neely Jonathan Castillo Michele Ramos Correa Pablo E Puente

Front Oncol

November 2023

Lung cancer is the leading cause of cancer death in the United States and worldwide, and a major source of cancer health disparities. Lung cancer cell lines provide key models for molecular studies of lung cancer development and progression, and for pre-clinical drug testing. To ensure health equity, it is imperative that cell lines representing different lung cancer histological types, carrying different cancer driver genes, and representing different genders, races, and ethnicities should be available.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Pablo E Puente"

  • - Pablo E Puente's recent research focuses on understanding the implications of KRAS mutations in lung cancer, specifically targeting therapy that disrupts hyperactive G-protein signaling associated with these mutations.
  • - His study on polyisoprenylated cysteinyl amide inhibitors (PCAIs) demonstrates their potential to induce apoptosis and inhibit cell migration in KRAS-mutated lung adenocarcinoma cells derived from Black Americans.
  • - Puente highlights the critical lack of racial and ethnic diversity in lung cancer cell lines, stressing the need for more representative models to address health disparities and ensure equitable cancer treatment and drug testing.

Privacy Policy Site Map

© LitMetric 2024. All rights reserved.